Our CEO roundtable brings founders and chief officers of peptide focused companies together to share their experiences and lessons learned during various stages of peptide drug discovery and development and discuss their visions of future opportunities and challenges in the peptide space. These visions, lessons and experiences, most of them hard earned will help guide the audience to better understand the peptide industry, appropriately set expectations, rationally prioritize research/career path, strategically prepare for and overcome challenges and ultimately lead to success.
| Dave Garman
Chief Technology Officer, NoNo Inc
Chief Scientific Officer, Xeris Pharmaceuticals, Inc.
President and CEO, Ambiopharm Inc.
Networking reception on the St Julien patio with hor d'oeuvres and drinks
By Invite Only
This workshop will focus on analytical techniques appropriate to verify that a peptidic API or Drug Product is fit for use and fulfill the measurable CQAs during release activities. These tests should be appropriate to assure Patients’ Safety.
Manager Method Development, Bachem
|Defining Critical Quality Attributes of the Peptide API: A Summary of Analytical Techniques used to Determine the Appropriate Analytical Target Profile for Peptide Drug Substances|
|Jorgen Kjellgren Sjogren
Senior Research Scientist, Ferring
|Analytical challenges in fate of impurities investigations for Ferrings synthetic peptides, downstream and upstream samples.|
Founder and CEO Drug Delivery Experts
|Identifying Critical Quality Attributes in Drug Product Development – A case Study to Support the Development of Generic Peptide Drug Product|
Networking Reception on the Patio with Open Bar
Boxed lunches will be provided